共查询到20条相似文献,搜索用时 995 毫秒
1.
3-氨基-4-氧代氰基呋咱捕获与表征 总被引:1,自引:0,他引:1
3,4-双(4-氨基呋咱-3-基)氧化呋咱由活性中间体3-氨基-4-氧代氰基呋咱分子间发生二聚获得,但3-氨基-4-氧代氰基呋咱不稳定,无法通过分离、纯化及光谱鉴定证实其存在.采用4种不同的烯烃与3-氨基-4-氧代氰基呋咱发生1,3-偶极环加成反应得到3-(4-氨基呋咱-3-基)-5-氰基-Δ2-异噁唑啉、3-(4-氨基呋咱-3-基)-5-乙酰氧基-Δ2-异噁唑啉、3-(4-氨基呋咱-3-基)-5-正丁基-Δ2-异噁唑啉及3-(4-氨基呋咱-3-基)-环己烷并-Δ2-异噁唑啉4种Δ2-异噁唑啉衍生物;采用苯甲酰氯为捕获剂,与3-氨基-4-氧代氰基呋咱反应获得了3-氨基-4-(N-苯甲酸基氨基羰基)呋咱化合物;通过红外光谱、核磁共振光谱、质谱、元素分析表征了5种新化合物的结构,提供了活性中间体3-氨基-4-氧代氰基呋咱存在的间接证据. 相似文献
2.
以3,5-二取代异噁唑-4-甲酰肼为基本原料制备关键中间体1-(3-对甲氧基苯基-5-甲基异噁唑-4-基)-4-芳基氨基硫脲(3a~3c);3在不同条件下经关环反应制得含有3,5-二取代异噁唑的2-芳氨基噻二唑(4a~4c),2-芳氨基噁二唑(5a~5c)和3-[3’-(4″-甲氧基苯基)-5’-甲基-异噁唑-4’-基)-4-芳基-1,2,4-三唑-5-硫酮(6a~6c);6与碘甲(乙)烷反应合成了4-芳基-5-[3’-(4″-甲氧基苯基)-5’-甲基异噁唑-4’-基]-3-甲(乙)硫基-1,2,4-三唑(7a~8c),其结构经1H NMR,IR,MS和元素分析表征,其中4,5,7和8未见文献报道。 相似文献
3.
以3,5-二取代异噁唑-4-甲酰肼为基本原料制备关键中间体1-(3-对甲氧基苯基-5-甲基异噁唑-4-基)-4-芳基氨基硫脲(3a~3c);3在不同条件下经关环反应制得含有3,5-二取代异噁唑的2-芳氨基噻二唑(4a~4c),2-芳氨基噁二唑(5a~5c)和3-[3′-(4"-甲氧基苯基)-5′-甲基-异噁唑4′-基)-4-芳基-1,2,4-三唑-5-硫酮(6a~6c);6与碘甲(乙)烷反应合成了4-芳基-5-[3′-(4″-甲氧基苯基)-5′-甲基异噁唑-4′-基]-3-甲(乙)硫基-1,2,4-三唑(7a~8c),其结构经1H NMR,IR,MS和元素分析表征,其中4,5,7和8未见文献报道. 相似文献
4.
3-N-乙酰基-2-取代芳基-5-[5'-甲基-异噁唑-3']-Δ3-1,3,4-噁唑啉类化合物的合成 总被引:31,自引:0,他引:31
甲基-异噁唑甲酰肼;3-N-乙酰基-2-取代芳基-5-[5'-甲基-异噁唑-3']-Δ3-1;3;4-噁唑啉类化合物的合成 相似文献
5.
6.
以6-氯-3-吡啶甲醛为原料, 通过多步反应合成了一系列3-(吗啉吡啶基)-5-取代异噁唑类化合物, 并用IR, 1H NMR, 13C NMR和MS进行了结构确证. 这些化合物均以异噁唑为母核, 具有近似的平面结构, 在异噁唑环的3-位引入吗啉吡啶基, 而在5-位引入酯基、取代氨基、三唑环和噁唑烷酮环. 研究了这些化合物对金黄色葡萄球菌、耐甲氧西林金黄色葡萄球菌、表皮葡萄球菌、粪肠球菌和大肠杆菌的抑制活性, 发现与噁唑烷酮类上市药物利奈唑胺相比, 目标化合物均显示出更低的抗菌活性, 最低抑制浓度(MIC)大于32 mg/L, 这些试验结果表明异噁唑母核的5-位缺乏sp3杂化结构, 可能会导致抗菌活性的显著降低. 相似文献
7.
8.
9.
用飞秒Ti:sapphire激光测定了3个对称噁二唑衍生物4-{N,N-双[4-(4-[5-(4-叔丁基苯基)-1,3,4-噁二唑-2]苯乙烯基)苯基]氨基}苯甲醛(Bis-oxa)、2,5-双{4-[2-N,N-双(4-{4-[5-(4-叔丁基苯基)-1,3,4-噁二唑-2]苯乙烯基}苯基)氨基苯乙烯基]苯基}-1,3,4-噁二唑(Quadri-oxa)和2,5-双(4-{2-N,N-双[({3,5-二[5-(4-叔丁基苯基)-1,3,4-噁二唑-2]苯基}乙烯基)苯基]氨基苯乙烯基}苯基)-1,3,4-噁二唑(Octu-oxa)的三光子吸收谱和三光子荧光光谱. 在1260 nm飞秒激光激发下, 2,4和8-支噁二唑衍生物的三光子吸收系数分别为5.0×10-5, 10.0×10-5和10.0×10-5 cm3/GW2, 三光子频率上转换荧光发射波长分别为533, 544和551 nm. 研究了多支化合物线性吸收和透过、单光子荧光及量子产率、荧光寿命、多光子荧光光谱和三光子吸收系数谱. 对称多支噁二唑衍生物具有很强的三光子吸收和上转换荧光性质. 相似文献
10.
11.
以取代苯甲醛为原料,经Wittig反应、水解反应和NaBH4还原反应制得5个取代苯乙醇衍生物(4a~4e);以4a~4e和其他芳乙醇(4f~4r)为原料,依次与全乙酰化溴代葡萄糖经Koenigs-Knorr偶联和MeONa/MeOH脱除乙酰保护基,合成了18个取代苯乙醇葡萄糖氧苷类似物(5a~5r,其中5b~5r为新化合物),其结构经1H NMR和HR-MS(ESI)表征。采用MTT法研究了5a~5r对缺氧损伤的内皮细胞(EA.hy926)代谢活力的影响。结果表明:5e, 5g, 5m, 5p, 5q和5r对EA.hy926的保护作用优于红景天苷。 相似文献
12.
13.
14.
用密度泛函理论(DFT)研究了As-5、[As5M]-和[As5MAs5]2- (M=Ti, Zr, Hf)的结构、频率、能量以及芳香性, 详细讨论了体系中不同类型的键和电子如化学键、孤对电子、核电子等对总的核独立化学位移(NICS)的影响. 结果表明, As-5、[As5M]-和[As5MAs5]2-的基态结构分别具有D5h、C5v和D5h对称性, 而且都具有芳香性. As-5 (D5h)的芳香性主要来源于As—As π键和As—As σ键的作用. [As5M]-(C5v)中各种As—M键的NICS分割值占主要优势, 其次是As—As之间形成的σ键. [As5TiAs5]2-(D5h)中, As—As π键的作用占主要优势. [As5ZrAs5]2-(D5h)中, As—As π键对体系总的NICS贡献相对减小, 而As—Zr键的作用增强. [As5HfAs5]2-(D5h)的芳香性主要来自As—Hf键的作用. 相似文献
15.
16.
Baldridge KK Donovan-Merkert BT O'Connor JM Lee LI Closson A Fandrick D Tran T Bunker KD Fouzi M Gantzel P 《Organic & biomolecular chemistry》2003,1(5):763-766
The metal-enediyne complexes [(eta 5-C5H5)Fe[eta 5-1,2-C5H3C identical to C(CH2)nC identical to]] (4, n = 4; 5, n = 5) and [(eta 5-C5H5)-Fe[eta 5-1,2-C5H3(C identical to C Me)2]] (6) were prepared from 1,2-diethynylferrocene (3). Complexes 4 and 5 were characterized in the solid state by X-ray crystallographic analysis. The structures of 4 and 6 were determined by computation using ab initio methods. A correlation was observed between ring-strain and increased ease of electrochemical oxidation along the series 6 (+0.164 V) to 5(+0.152 V) to 4 (+0.123 V). A similar trend in ionization potentials was identified in both the gas phase and in solution by computational methods. 相似文献
17.
以取代苯甲醛(1a~1t)为原料,通过Knoevenagel缩合、酯化和LiAlH4还原等反应制得苯丙烯醇衍生物(3a~3t);以取代肉桂醛(1u~1x)为原料,经NaBH4还原制得苯丙烯醇衍生物(3u~3x); 3a~3x与全乙酰化溴代葡萄糖经Koenigs-Knorr偶联反应及MeONa/MeOH体系脱除乙酰保护基反应,合成了24个苯丙烯类葡萄糖氧苷(5a~5x),其中5c,5f ~ 5x为新化合物,其结构经1H NMR和ESI-MS表征。采用MTT法测定了5对缺氧损伤的内皮细胞(EA.hy926)的抗缺氧活性。实验结果表明: 5b, 5e, 5g, 5p, 5q, 5s, 5t和5y对EA.hy926的抗缺氧活性均高于经景天苷。 相似文献
18.
19.
Simultaneous HPLC determination of 5-fluorouracil and its metabolites in plasma of cancer patients 总被引:1,自引:0,他引:1
Casale F Canaparo R Muntoni E Serpe L Zara GP Della Pepa C Berno E Costa M Eandi M 《Biomedical chromatography : BMC》2002,16(7):446-452
5-Fluorouracil (5-Fu) is a commonly used anticancer agent for treatment of solid tumours. Certain studies have reported conflicting results between individual plasma concentration levels and toxicity or therapeutic effects. For this reasons some authors proposed to evaluate the plasma levels of 5-Fu metabolites 5-fluorouridine, 5-fluoro-2'-deoxyuridine and 5-fluoro-5,6-dihydro-uracil. The aim of the present work is to develop and validate a new HPLC method simultaneously determining 5-fluorouracil and its three metabolites, to be used to study the plasma levels, therapeutic effects and toxicity in cancer patients. The analytes were separated on a 4.6 x 250 mm ODS1 (5 micro m) not end-capped column, operating at room temperature. Elution was performed under isocratic conditions, employing a 1.5 mM K(3)PO(4) mobile phase (pH 5). 5-Bromo-5,6-dihydro-uracil was used as internal standard. The limits of quantitation were 0.5 micro g/mL for 5-fluorouracil, 1 micro g/mL for 5-fluoro-5,6-dihydro-uracil, 3 micro g/mL for 5-fluoro-2'-deoxyuridine and 5-fluorouridine; the stability, recovery, linearity, accuracy and specificity of the compounds were evaluated according to the criteria widely accepted. Using this method we measured plasma samples of 18 cancer patients treated with folinic acid (100 mg/m(2)) by intravenous administration, followed by an i.v. bolus of 5-Fu (400 mg/m(2)). The concentration levels of 5-fluorouracil and for 5-fluoro-5,6-dihydro-uracil were detectable in all the subjects while 5-fluorouridine and 5-fluoro-2'-deoxyuridine were present only in eight patients. 相似文献
20.
以雄甾-4-烯-3,17-二酮(AD)为起始原料, 合成了14个甾体17位肟醚和肟酯类新化合物. 所合成的化合物结构均经过MS, 1H NMR谱确证, 并对所合成的化合物进行了老鼠5α-还原酶抑制生物活性初步评价. 结果表明: 受试化合物均有一定的5α-还原酶抑制活性, 其中化合物5a, 5c, 5d有较高的5α-还原酶抑制活性, 与参比药物Espristeride相当. 相似文献